

Mark Lythgoe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6679561/publications.pdf>

Version: 2024-02-01

44
papers

1,118
citations

516215

16
h-index

433756

31
g-index

44
all docs

44
docs citations

44
times ranked

2020
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of prior local therapy and outcomes with programmedâ€death ligandâ€1 inhibitors in advanced urothelial cancer. <i>BJU International</i> , 2022, 130, 592-603.	1.3	3
2	The potential of fecal microbiota transplantation in oncology. <i>Trends in Microbiology</i> , 2022, 30, 10-12.	3.5	9
3	Disparity of race reporting in US Food and Drug Administration drug approvals for urinary system cancers from 2006 to 2021. <i>BJU International</i> , 2022, 129, 168-170.	1.3	3
4	The last word to new FDA draft guidance for cancer clinical trial eligibility criteria for patients with incurable cancer. <i>Journal of Cancer Policy</i> , 2022, 31, 100322.	0.6	0
5	Cancer Drug Approvals That Displaced Existing Standard-of-Care Therapies, 2016-2021. <i>JAMA Network Open</i> , 2022, 5, e222265.	2.8	26
6	High US drug prices have global implications. <i>BMJ, The</i> , 2022, 376, o693.	3.0	7
7	Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 165-175.	0.9	4
8	Approved anti-PD-1 monoclonal antibodies in China: A bridge too far for US approval. <i>European Journal of Cancer</i> , 2022, 169, 103-105.	1.3	5
9	Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019. <i>JAMA Network Open</i> , 2022, 5, e2216183.	2.8	27
10	Repositioning canakinumab for non-small cell lung cancerâ€important lessons for drug repurposing in oncology. <i>British Journal of Cancer</i> , 2022, 127, 785-787.	2.9	16
11	CostPlus and implications for generic imatinib. <i>The Lancet Regional Health Americas</i> , 2022, 13, 100317.	1.5	1
12	Advances in cyclin-dependent kinase inhibitors for the treatment of melanoma. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 351-361.	0.9	10
13	Development and economic trends in anticancer drugs licensed in the UK from 2015 to 2019. <i>Drug Discovery Today</i> , 2021, 26, 301-307.	3.2	8
14	Safe administration of chemotherapy in mast cell activation syndrome. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1005-1010.	0.5	1
15	Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. <i>BJU International</i> , 2021, 128, 196-205.	1.3	18
16	Race reporting and diversity in US food and drug administration (FDA) registration trials for prostate cancer; 2006â€2020. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1208-1211.	2.0	11
17	V6â€PRIMROSE: A national trainee collaborative-led, multicentre prospective audit on the care of breast cancer patients with central nervous system disease in the UK. <i>BJS Open</i> , 2021, 5, .	0.7	0
18	Comparison of COVID-19 Vaccine Approvals at the US Food and Drug Administration, European Medicines Agency, and Health Canada. <i>JAMA Network Open</i> , 2021, 4, e2114531.	2.8	28

#	ARTICLE	IF	CITATIONS
19	A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors. <i>European Urology Oncology</i> , 2021, 4, 464-472.	2.6	39
20	Gene of the month: lymphocyte-activation gene 3 (LAG-3). <i>Journal of Clinical Pathology</i> , 2021, 74, 543-547.	1.0	35
21	The Oncologic Drugs Advisory Committee Votes of April 2021â€™ Implications for the Fate of Accelerated Approval. <i>JAMA Oncology</i> , 2021, 7, 1607-1609.	3.4	14
22	Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia. <i>Cancers</i> , 2021, 13, 4232.	1.7	3
23	Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. <i>Cancers</i> , 2021, 13, 4181.	1.7	0
24	The FDAâ€™s latest move to expand eligibility for oncology trials â€™ a double-edged sword?. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 745-746.	12.5	1
25	How the US Food and Drug Administrationâ€™s approval of aducanumab for Alzheimer's disease has implication for oncology and beyond. <i>European Journal of Cancer</i> , 2021, 157, 68-70.	1.3	7
26	Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000739.	1.1	26
27	The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. <i>European Journal of Cancer</i> , 2021, 159, 56-59.	1.3	1
28	Characteristics of Cost-effectiveness Studies for Oncology Drugs Approved in the United States From 2015-2020. <i>JAMA Network Open</i> , 2021, 4, e2135123.	2.8	20
29	The impact of new cancer drug therapies on site specialised cancer treatment activity in a UK cancer network 2014â€™2018. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 93-98.	0.5	5
30	Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 1208-1216.	2.0	70
31	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	0.8	135
32	Regorafenib therapy for hepatocellular carcinoma in a HIVâ€™-infected patient: A case report. <i>Liver Cancer International</i> , 2020, 1, 51-54.	0.2	2
33	Oncologist-led BRCA â€™mainstreamingâ€™ in the ovarian cancer clinic: A study of 255 patients and its impact on their management. <i>Scientific Reports</i> , 2020, 10, 3390.	1.6	34
34	Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 363-382.	4.0	311
35	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.2	32
36	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. <i>F1000Research</i> , 2020, 9, 1193.	0.8	41

#	ARTICLE	IF	CITATIONS
37	The worldwide clinical trial research response to the COVID-19 pandemic - the first 100 days. F1000Research, 2020, 9, 1193.	0.8	38
38	Response to letter to editor regarding published article "metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Familial Cancer, 2018, 17, 545-546.	0.9	1
39	Metachronous colorectal cancer following segmental or extended colectomy in Lynch syndrome: a systematic review and meta-analysis. Familial Cancer, 2018, 17, 557-564.	0.9	36
40	Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future., 2016, 164, 195-203.		37
41	Good practice in shared care for inflammatory arthritis. British Journal of General Practice, 2016, 66, 275-277.	0.7	9
42	Tacrolimus: an effective treatment in refractory psoriatic arthritis following biologic failure. Clinical and Experimental Rheumatology, 2016, 34, S12-3.	0.4	3
43	Application of "Systems Vaccinology" to Evaluate Inflammation and Reactogenicity of Adjuvanted Preventative Vaccines. Journal of Immunology Research, 2015, 2015, 1-11.	0.9	41
44	Effective antidotes for new anticoagulants. BMJ, The, 2015, 350, h2775-h2775.	3.0	0